Allergan and Target PharmaSolutions join to fight certain type of liver disease

Allergan will collaborate with Target PharmaSolutions on its five-year longitudinal observational study that looks at patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

The study, known as TARGET-NASH study, was launched in advance of related drug approvals in order to help facilitate a greater understanding of the impact of NASH and future treatment options.

David Nicholson, Chief Research & Development Officer, Allergan commented cooperation: “NASH is an emerging healthcare crisis affecting both adults and children. This unique collaboration will help to further our collective understanding of the disease, effective modes of treatment and outcomes across the spectrum of patient groups.”

Allergan explained that the study design is disease focused, not drug specific, allowing for continuous acquisition of natural history and outcomes data as new drugs enter the market and clinical treatment paradigms evolve.

“TARGET-NASH is critical for the scientific and regulatory community as we prepare for new agents for the treatment of NASH,” said Arun Sanyal, MD, Co-Chair, TARGET-NASH Steering Committee. “In the immediate term, it will give us a critical understanding of NASH diagnosis and management in the real world across multiple populations.  In the longer term, it is the perfect platform to have a deep understanding of the safety and effectiveness of these new agents across populations not included or underrepresented in Phase 3 clinical trials.”